- Overall incidence of childhood cancer is on the increase, averaging 0.8% increase per year since 1975, reports leading advocacy organization
- QSAM developing therapeutic radiopharmaceuticals as safer, more efficacious alternatives to address unmet medical needs, underserved patient populations
- Company creating pipeline of novel radiotherapeutics to serve multiple indications with its lead product, CycloSam
With the overall incidence of childhood cancer on the rise, the work of QSAM Biosciences (OTCQB: QSAM) is becoming increasingly important. QSAM Biosciences is a clinical-stage biotechnology company focused on developing and bringing to market targeted therapeutic radiopharmaceuticals and advancing the fight against cancer, including the underserved pediatric population.
“The overall incidence of childhood cancer is on the increase, averaging 0.8% increase per year since 1975. Overall cancer incidence rates increased an average of 1% per year from 1997 to 2018,” reports Children’s Cancer Cause, the leading national advocacy organization for children’s cancer (https://ibn.fm/foz9V).
According to Children’s Cancer Cause, in 2022 an estimated 10,470 children (from birth to 14 years) and 5,480 adolescents (aged 15 to 19 years) will be diagnosed with cancer. “It is estimated that there will be 13.7 million cases of childhood cancer between 2020-2050. Unless there are major improvements in diagnosis and treatments, of this, 45% will go undiagnosed and 11.1 million will die if no further investments in interventions are made. The vast majority, almost 85%, will be concentrated in developing countries.”
The group went on to note that cancer in children and young adults is different from cancer that develops in adults. “Some of the unwanted side effects of cancer treatments cause more harm to children than they do to adults,” the report states. “This is because children’s bodies are still growing and developing, so cancer and its treatment are more likely to affect developing organs.
“More than 95% of childhood cancer survivors will have a significant health-related issue by the time they are 45 years of age,” the report continued. “These health-related issues are side effects of either the cancer or, more commonly, the result of its treatment: one-third will suffer severe and chronic side effects, one-third will suffer moderate to severe health problems, and one-third will suffer slight to moderate side effects.”
QSAM Biosciences is working to make a difference in this space, as well as in the adult cancer sector. The company is developing “targeted therapeutic radiopharmaceuticals as safer and more efficacious alternatives to current treatment modalities to address large unmet medical needs and underserved patient populations” (https://ibn.fm/gE7c6).
With that in mind, QSAM is focused on creating a pipeline of novel radiotherapeutics to serve multiple indications. The company’s lead product, CycloSam(R), is a clinical-stage, bone-seeking radiopharmaceutical designed to deliver targeted radiation safely and precisely to tumors in the bone.
“CycloSam delivers the beta-emitting radioisotope, Samarium-153, to areas of rapid bone formation through a superior chelant, DOTMP, emitting a potent yet controlled dose of radiation treatment directly to the tumor environment while minimizing radiation exposure to healthy tissue,” the company reports. “The results we seek are halting or regressing primary and metastatic tumors in bone for both children and adults. . . . CycloSam is the next generation of an already FDA-approved drug, with patented improvements to increase efficacy and utility, reduce toxicity, and streamline production.”
For more information, visit the company’s website at www.QSAMbio.com.
NOTE TO INVESTORS: The latest news and updates relating to QSAM are available in the company’s newsroom at http://ibn.fm/QSAM
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
San Francisco, California
BioMedWire is part of the InvestorBrandNetwork.